Thursday, March 10, 2016

Seeking Alpha: Celldex Demonstrates That Cancer Is Hard

Monday brought very disappointing news, as Celldex (NASDAQ:CLDX) announced that the second interim analysis of the Phase III study of its lead drug Rintega (rindopepimut) failed to show a survival benefit relative to the control arm (Temodar). As a result, the company is stopping the trial and ending further development of what was expected to be the company's first drug to reach the market.

This is a surprising (if not shocking) result relative to past trial results that showed a consistent survival advantage for Rintega, but the data are what they are. Celldex still has a credibly deep pipeline of immuno-oncology drugs, but it is likely going to take a little while for investors to get over this disappointment and consider Celldex again as an investment.

Click here to continue:
Celldex Demonstrates That Cancer Is Hard

No comments: